COX-2/5-LOX-IN-3
Modify Date: 2025-09-16 11:03:53
COX-2/5-LOX-IN-3 structure
|
Common Name | COX-2/5-LOX-IN-3 | ||
|---|---|---|---|---|
| CAS Number | 2481484-51-7 | Molecular Weight | 361.85 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C17H16ClN3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of COX-2/5-LOX-IN-3COX-2/5-LOX-IN-3 (compound 5b) is a potent and dual COX-2/5-LOX inhibitor with IC50 values of 45.73, 5.45 and 4.33 μM for COX-1, COX-2, and 5-LOX, respectively. COX-2/5-LOX-IN-3 has the potential for the research of inflammation diseases[1]. |
| Name | COX-2/5-LOX-IN-3 |
|---|
| Description | COX-2/5-LOX-IN-3 (compound 5b) is a potent and dual COX-2/5-LOX inhibitor with IC50 values of 45.73, 5.45 and 4.33 μM for COX-1, COX-2, and 5-LOX, respectively. COX-2/5-LOX-IN-3 has the potential for the research of inflammation diseases[1]. |
|---|---|
| Related Catalog | |
| Target |
COX-2:5.45 μM (IC50) COX-1:45.73 μM (IC50) 5-LOX:4.33 μM (IC50) |
| In Vivo | COX-2/5-LOX-IN-3 (compound 5b) (p.o.; male Sprague Dawley rats) shows anti-inflammatory activities in vivo[1]. Animal Model: Male Sprague Dawley rats[1] Dosage: 2.622 X 10-5 mol/kg Administration: Oral administration Result: The percentage inhibition of edema (%I) reached 58.77% after 4h. |
| References |
| Molecular Formula | C17H16ClN3O2S |
|---|---|
| Molecular Weight | 361.85 |